Risk of Neuroendocrine Neoplasms with Glucagon-Like-Petide-1 Receptor Agonist Use in Patients with Type 2 Diabetes Mellitus
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Prior studies demonstrate reduced risk of several malignancies among patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like-peptide-1 receptor agonists (GLP-1RA). A recent study however found expression of GLP-1R among neuroendocrine neoplasm (NEN) cell lines and growth promotion in xenografts treated with semaglutide. In this study, we evaluate incidence of NENs among patients diagnosed as overweight/obese and patients with T2DM prescribed GLP-1RA based drugs.
Methods
The TriNetX database was utilized for this study. Incidence of NENs between patients with overweight/obesity were compared to a control group without obesity within 15 years following index diagnosis of obesity or, in the control group, a non-specific outpatient visit. Groups were matched for demographics, tobacco use, family malignancy history, alcohol use, and socioeconomic factors. In a separate analysis, incidence of NENs among patients with T2DM were compared between those prescribed GLP-1RAs versus other antihyperglycemic agents (AHA) within 15 years following index prescription of GLP-1RA or comparator AHA. Patients with exposure to the comparator AHA were excluded from their respective groups. A subgroup analysis was performed among patients with overweight/obesity. Exclusion criteria included Merkel cell carcinoma, multiple endocrine neoplasia type 1, Cushing’s syndrome, Von Hippel-Lindau syndrome, tuberous sclerosis, and prior NEN.
Results
Patients with overweight/obesity had a significant increased risk of NENs when compared to the control group (3,840/794,235 (0.48%) vs. 2,785/794,235 (0.35%); RR: 1.38 (95% CI 1.31-1.45), P < 0.0001). Among patients with T2DM, GLP-1RA exposure was associated with significantly lower risk of NENs compared to insulin (70/31,171 (0.23%) vs. 137/31,171 (0.44%); RR: 0.51 (0.38, 0.68), P < 0.0001), but no significant difference was appreciated with other AHAs. In the subset of patients with obesity/overweight, GLP-1RAs were associated with decreased risk compared to insulin (43/15,230 (0.28%) vs. 68/15,230 (0.45%); RR: 0.63 (0.43, 0.93), p=0.02) and metformin (39/10,370 (0.38%) vs. 64/10,370 (0.62%); RR: 0.61 (0.41, 0.91), P = 0.01).
Conclusion
This study suggests obesity to be significantly associated with incidence of NENs. Furthermore, our findings do not demonstrate an increased incidence of NENs with GLP-RA use among patients with T2DM and show decreased risk when compared to insulin exposure.
